Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kinesin family member 25 (KIF25) is a minus-end directed microtubule motor protein of the kinesin-14 subfamily, expressed ubiquitously in human tissues[1][3][4][5]. It operates as a tetramer and is localized to centrosomes throughout the cell cycle[7]. KIF25 acts as a negative regulator of centrosome separation, tethering duplicated centrosomes together during interphase and helping to maintain a centered nucleus, thereby ensuring proper spindle orientation at mitosis onset[1][4][7]. Loss of KIF25 results in premature centrosome separation, nuclear mispositioning, and defects in spindle orientation, which may impact accurate chromosome segregation[7]. KIF25 has also been implicated, more generally as a member of the kinesin family, in cancer progression and as a possible contributor to disease phenotypes related to cell division and centrosomal defects[2][4]. There are no reported drugs directly targeting KIF25, and its precise role in human diseases, as well as its potential as a clinical biomarker or safety liabilities, remain underexplored.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kinesin family member 25 (KIF25).